Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2024

Non-small cell lung cancer (NSCLC) is a form of epithelial lung cancer that originates in the lung tissues, marked by the abnormal proliferation of cells. The primary causes of NSCLC include long-term smoking, genetic mutations, exposure to air pollution, and secondhand smoke.

The main subtypes of non-small cell lung cancer (NSCLC) are squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma originates from squamous epithelial cells and can manifest in various parts of the body. A variety of therapeutic approaches are employed for NSCLC, including radiotherapy, laser therapy, photodynamic therapy (PDT), and others. These therapeutic options are distributed through different channels, including hospital pharmacies, online pharmacies, and others.

The non-small cell lung cancer (NSCLC) market research report is one of a series of new reports that provides non-small cell lung cancer (NSCLC) market statistics, including non-small cell lung cancer (NSCLC) industry global market size, regional shares, competitors with a non-small cell lung cancer (NSCLC) market share, detailed non-small cell lung cancer (NSCLC) market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (NSCLC) industry. This non-small cell lung cancer (NSCLC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-small cell lung cancer (nsclc) market size has grown rapidly in recent years. It will grow from $18.02 billion in 2023 to $20.1 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth observed in the historical period can be attributed to several factors, including the evolution of immunotherapy, advancements in genomic profiling and precision medicine, the expansion of clinical trials, and initiatives focused on smoking cessation.

The non-small cell lung cancer (nsclc) market size is expected to see rapid growth in the next few years. It will grow to $29.95 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The anticipated growth in the forecast period can be attributed to emerging combination therapies, the integration of artificial intelligence (AI) in cancer treatment, the expansion of personalized vaccines, global collaborations in research, and the focus on patient-centric care. Notable trends expected in the forecast period include the integration of telemedicine in oncology, the utilization of liquid biopsy technologies, advances in diagnostic technologies, the adoption of minimally invasive surgical techniques, and the continued use of immune checkpoint inhibitors.

The anticipated rise in tobacco consumption is poised to drive the growth of the non-small cell lung cancer (NSCLC) market. Tobacco consumption, involving the use of tobacco products through smoking, chewing, or snuffing, introduces nicotine and other harmful chemicals into the body. Tobacco smoke, laden with carcinogens, can damage DNA in lung cells, leading to mutations and uncontrolled growth of cancerous cells, including non-small cell lung cancer (NSCLC). For example, Statistics Canada reported in July 2022 that cigarette production increased by 5.8% compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Consequently, the escalating rate of tobacco consumption is a significant driver of the NSCLC market.

The anticipated growth of the non-small cell lung cancer (NSCLC) market is further driven by increasing air pollution. Harmful substances in the atmosphere, constituting air pollution, can adversely affect human health, increasing the risk of NSCLC through inflammation, DNA damage, and mutations in lung cells. The World Health Organization reported in June 2023 that air and household air pollution were linked to 7 million premature deaths annually. Additionally, approximately 2.4 billion people are exposed to dangerous levels of household air pollution. The World Bank further highlighted in September 2022 that health damage from air pollution amounts to $8.1 trillion annually, equivalent to 6.1% of global GDP. Thus, the growth of non-small cell lung cancer (NSCLC) is expected to be propelled by increasing air pollution.

Despite the growth prospects, the non-small cell lung cancer (NSCLC) market may face hindrances due to the medication side effects associated with treatments such as immunotherapy. While immunotherapy has significantly improved survival and quality of life for NSCLC patients with fewer side effects than traditional chemotherapy, over 40% of patients, as reported by the National Cancer Institute in April 2021, experienced immune-related side effects that persisted for at least three months after stopping treatment with immune checkpoint inhibitors. This has implications for the growth of the NSCLC market.

Major companies in the non-small cell lung cancer (NSCLC) market are strategically developing multiple treatment options, including monotherapy treatments, to gain a competitive advantage. Monotherapy treatment, utilizing a single drug or therapy to address medical disorders, provides a focused approach. For instance, in June 2022, Novartis AG gained approval from the European Commission for Tabrecta (capmatinib) to treat adult patients with advanced NSCLC with METex14 skipping. This targeted therapeutic option addresses mutations causing MET exon 14 (METex14) skipping.

In August 2022, Bristol-Myers Squibb's acquisition of Turning Point Therapeutics for $4.1 billion enhances its ability to treat ROS1-positive NSCLC patients with the promising therapy, repotrectinib, developed by Turning Point Therapeutics. Repotrectinib holds the potential to improve outcomes for patients with ROS1-positive non-small-cell lung cancer. Turning Point Therapeutics specializes in developing precision medicines for NSCLC.

Major companies operating in the non-small cell lung cancer (nsclc) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines.

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-small cell lung cancer (nsclc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.